Continue Reading
Full article on Bloomberg
Merck to Buy Cidara in $9.2B Deal as Patent Deadline Looms
{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}Market Intelligence Analysis
AI-Powered
Why This Matters
Merck agreed to acquire Cidara Therapeutics for $9.2 billion, as it looks to offset the patent loss of its cancer drug Keytruda. Merck will pay $221.50 per share in cash, more than double the closing price, to acquire the biotech company. This deal is part of Merck's efforts to bolster its pipeline and mitigate potential losses.
Market Impact
Market impact analysis based on bullish sentiment with 79% confidence.
Sentiment
Bullish
AI Confidence
79%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda. Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total transaction value of about $9.2 billion, the companies said Friday in a statement. Bloomberg's Madison Muller joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)
Original article published by
Bloomberg
on November 14, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.